Relevance of chronic hepatitis E in liver transplant recipients: A real-life setting

Transplant Infectious Disease

Volumn 17, Issue 4, 2015, Pages 617-622

  Galante, A ^a   Pischke, S ^a   Polywka, S ^a   Luetgehethmann, M ^a   Suneetha, P V ^b   Gisa, A ^b   Hiller, J ^a   Dienes, H P ^c   Nashan, B ^a   Lohse, A W ^a   Sterneck, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic hepatitis E; Liver transplant recipients; Real life setting; Ribavirin; Screening; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTAME; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CYCLOSPORIN; EVEROLIMUS; LIVER ENZYME; MYCOPHENOLATE MOFETIL; RIBAVIRIN; STEROID; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL CULTURE; CHRONIC HEPATITIS; CHRONIC HEPATITIS E; CHRONIC LIVER DISEASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FUNCTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER GRAFT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PORTAL VEIN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SCLEROSING CHOLANGITIS; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS GENOME; ADOLESCENT; HEPATITIS, CHRONIC; LIVER TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS E; HEPATITIS, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938588811     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12411     Document Type: Article

References (15)

1. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-817.
2. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142: 1388-1397.
3. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010; 16: 74-82.
4. Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis E in heart transplant recipients. Am J Transplant 2012; 12: 3128-3133.
5. Pischke S, Greer M, Hardtke S, et al. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. Transpl Infect Dis 2014; 16: 333-339.
6. Pischke S, Behrendt P, Bock CT, Jilg W, Manns MP, Wedemeyer H. Hepatitis E in Germany - an under-reported infectious disease. Dtsch Arztebl Int 2014; 111: 577-583.
7. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-1489.
8. Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010; 50: e30-e33.
9. Haagsma E, Riezebos-Brilman A, Van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 2010; 16 (4): 474-477.
10. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single center experience. Liver Int 2013; 33: 722-726.
11. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-1120.
12. Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 2014; 147 (5): 1008-1011.e7; quiz e15-16.
13. Garson JA, Ferns RB, Grant PR, et al. Minor groove binder modification of widely used TaqMan probe for hepatitis E virus reduces risk of false negative real-time PCR results. J Virol Methods 2012; 186: 157-160.
14. Moal V, Legris T, Motte A, et al. Systematic serological testing for hepatitis E virus in kidney transplant recipients. J Clin Microbiol Methods 2015; 53 (5): 1523-1530.
15. Abravanel F, Lhomme S, Chapuy-Regaud S, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J Infect Dis 2014; 209 (12): 1900-1906.